York academics to help shape access to medical database

UK Biobank is one of the biggest and most detailed public health research initiatives of our time. It involves collecting blood and urine samples, plus health and 'lifestyle' information, from 500,000 individuals aged between 40 and 69 years, and relating it to subsequent disease, cause of death and other factors over a period of 30 years.

The purpose of the UK Biobank project is to set up a resource to support a range of research to improve the prevention, diagnosis and treatment of illnesses and the promotion of health throughout society.

But the use of the samples and data by third parties, such as the pharmaceutical industry and academic researchers, raises a range of ethical questions such as, what should the terms of access be and what mechanism should be adopted for sharing the benefits from research? The new study by a team from the Science and Technology Studies Unit (SATSU) in the University’s Department of Sociology will help to ensure that policies already established by UK Biobank remain fit for purpose in the future.

The study is funded by the UK Biobank Ethics and Governance Council (EGC), an independent monitoring body which is funded by the Wellcome Trust and the Medical Research Council.

Dr Graham Lewis, one of the SATSU research team, said: “The UK Biobank project raises numerous scientific, ethical and logistical issues and its success will depend on an appropriate and robust policy for third party access.”

Professor Graeme Laurie, Chair of the EGC said: “The role of the EGC is to advise and monitor UK Biobank in developing the best possible policies for managing the research resource. This important study will provide us with a better understanding of public attitudes towards access issues, and this will feed directly into our advice to UK Biobank.”

All latest news from the category: Science Education

Back to home

Comments (0)

Write a comment

Newest articles

After 25 years, researchers uncover genetic cause of rare neurological disease

Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…

Lower dose of mpox vaccine is safe

… and generates six-week antibody response equivalent to standard regimen. Study highlights need for defined markers of mpox immunity to inform public health use. A dose-sparing intradermal mpox vaccination regimen…

Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids

EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…

Partners & Sponsors